Skip to search formSkip to main contentSkip to account menu

AZD 6244

Known as: AZD-6244, AZD6244, MEK inhibitor AZD6244 
National Institutes of Health

Related topics

Related topics

3 relations

Narrower (2)

ARRY 142886selumetinib

Broader (1)

Benzimidazoles

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
MAP2K1 Mutation in Colorectal Cancer Patients: Therapeutic Challenge Using Patient-Derived Tumor Cell Lines
BACKGROUND:The MAP2K1 K57T mutation is known to be a potential mechanism of primary and secondary resistance to EGFR inhibitors… 
2016
2016
A phase 1b study of Selumetinib in combination with Cisplatin and Gemcitabine in advanced or metastatic biliary tract cancer: the ABC-04 study (vol 16, 153, 2016)
2013
2013
Abstract 5538: Direct inhibition of ERK1/2 by VTX-11e leads to increased induction of apoptosis in a subset of pancreatic cancer cell lines as compared to MEK1/2 inhibition by selumetinib (AZD6244).
Background: Intense efforts to improve current molecular therapy in pancreatic ductal adenocarcinoma (PDAC) have focused on… 
2012
2012
The Akt Inhibitor MK 2206 Synergizes , but Perifosine Antagonizes , the BRAFV 600 E Inhibitor PLX 4032 and the MEK 1 / 2 Inhibitor AZD 6244 in the Inhibition of Thyroid Cancer Cells
Results: We found that MK2206 could potently, when used alone, and synergistically, when combined with either PLX4032 or AZD6244… 
2011
2011
Abstract 648: Combined PI3K and MEK inhibition in patient-derived xenografts generated from recurrent triple negative breast cancer
Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL Both the PI3K and ERK pathways have become critical… 
2010
2010
Clinical responses to AZD6244 (ARRY-142886)-based combination therapy stratified by gene mutations in patients with metastatic melanoma.
8501 Background: BRAF and NRAS mutations (mut) occur in 50-60% and 15-20% of melanomas, respectively. As a consequence, MAPK… 
2010
2010
Phase II study and tissue correlative studies of AZD6244 (ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma (IRPTC) and papillary thyroid carcinoma (PTC) with follicular elements.
5536 Background: There is no standard treatment for IRPTC. AZD6244 is an oral, small molecule inhibitor of the mitogen-activated… 
2008
2008
Efficacy and safety of AZD6244 (ARRY-142886) as second/third-line treatment of patients (pts) with advanced non-small cell lung cancer (NSCLC)
8029 Background: The Raf/MEK/ERK signaling pathway is necessary for oncogenic function, and in NSCLC pts constitutive activation… 
2008
2008
AZD6244 (ARRY-142886) versus capecitabine (CAP) in patients (pts) with metastatic colorectal cancer (mCRC) who have failed prior chemotherapy
• No standard of care exists for patients who experience disease progression after treatment with oxaliplatin/irinotecan-based… 
2008
2008
The first-in-human study of the solid oral dosage form of AZD6244 (ARRY-142886): A phase I trial in patients (pts) with advanced cancer
3535 Background: AZD6244 is a potent, selective, uncompetitive inhibitor of MEK1/2 being tested in phase II clinical trials for a… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)